

# CURRICULUM VITAE PROF. DR. MED. FRANCESCO (FRANCO) CAVALLI

Date of birth: July 03, 1942 Phone: +41 58 666 73 00  
Place of birth: Locarno, Switzerland E-Mail: franco.cavalli@ior.usi.ch  
Citizenship: Swiss ielsg@ior.usi.ch  
Marital status: Married, 7 children

## EDUCATIONAL BACKGROUND AND SPECIALITY BOARD

1968	M.D	University, Bern, Switzerland
1968-70	Intern-Resident, Psychiatry	University Psychiatry Hospital, Bern, Switzerland
1970-71	Intern, Internal Medicine	University Hospital, Bern, Switzerland
1972-73	Resident, Medical Oncology	University hospital, Bern, Switzerland
1973-74	Fellowship abroad	Institute Jules Bordet, Brussels, Belgium; Royal Marsden Hospital, London (U.K.); Istituto Tumori, Milan (Italy)
1975-78	Chief Resident, Hematology-Oncology	University Hospital, Bern, Switzerland
1978	Habilitation	University of Bern, Switzerland
1986	Extraordinary professor	Institution University of Bern, Switzerland
1993	Associate Professor	University of Varese, Italy
1995	Fellow	Royal College of Physician (F.R.C.P.), London

## POSITION HELD

1978-99	Head Division of Oncology	San Giovanni, Bellinzona, Ticino, Switzerland
1999-2011	Director	Institute of Oncology of Southern Switzerland, IOSI, Bellinzona, Switzerland
2011-07.2017	Scientific Director	Institute of Oncology of Southern Switzerland, IOSI, Bellinzona, Switzerland
2011-present	President	Institute of Oncology Research (IOR), Bellinzona, Switzerland

## MAIN PROFESSIONAL CHARGES

1981 - 1987	Chairman, Swiss Group for Clinical Cancer Research (SAKK)
1981 – present	President, Organizing Committee and Scientific Committee of International Conference on Malignant Lymphomas (ICML), Lugano
1982-1985	President Early Clinical Trials Group (ECTG) of EORTC
1985 - present	Member, Scientific Board of the European School of Oncology (ESO)
1985 - present	Member, Board European School of Oncology (ESO), Milan
1987 - 1993	Member, Board European Organization for Research on Treatment of Cancer (EORTC)
1987 - present	Member, Board Fondazione ticinese per la ricerca sul cancro
1989 - present	Member, Council Swiss Foundation for ESO
1990 - present	Member, Scientific Committee Steiner Prize, Foundation Steiner
1992 - 1995	Member, Scientific Committee European Haematological Association
1995 - 2007	Member, Swiss Parliament, Bern
1995 - 2017	President, Fondazione ticinese per la ricerca e la cura dei linfomi, Lugano
1997 - present	Founder and Coordinator of International Extranodal Lymphoma Study Group (IELSG), Bellinzona
1998	Member, International Expert Committee for the evaluation of the “Di Bella”-Therapy, Italian Government, Rome, Italy
2001 - 2004	Chairman, Swiss Cancer League
2002 - 2011	Member, Scientific Board Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid
2002 - 2012	Member, Review Committee Swiss National Program “Genomic in cancer”, Lausanne,
2004	President-elect Union Internationale Contre le Cancer /International Union Against Cancer (UICC) Geneva
2005 - 2011	Vice-President Scientific Committee, ESO (President: U. Veronesi), Milan
2006 - 2008	President Union Internationale Contre le Cancer/International Union Against Cancer (UICC), Geneva
2008 – 2010	Past President Union Internationale Contre le Cancer/ International Union Against Cancer (UICC), Geneva
2012 – present	Member Senate, Swiss Academy of Medical Sciences

June 2011 – present	President Scientific Committee European School of Oncology (ESO) President World Oncology Forum (WOF)
2017-present	President Foundation for the Institute of Oncology Research (IOR), Bellinzona
2019-present	Member Advisory Board AIRC (Associazione Italiana Ricerca Cancro)

#### MEMBERSHIPS

- European Society of Medical Oncology (ESMO): since 2002 Honorary Member
- European School of Oncology (ESO)
- Swiss Society for Medical Oncology (SGIO)
- American Association for Cancer Research (AACR)
- Italian Association for Clinical Oncology (AIOM)
- Swiss Society for Haematology
- American Society for Haematology (ASH)
- European Haematological Association (EHA)
- European Academy of Cancer Sciences
- Swiss Academy of Medical Sciences

#### MEMBER OF EDITORIAL BOARD (present)

- Haematological Oncology
- Cancer Therapy Update
- Leukaemia and Lymphoma
- Clinical Lymphoma
- The Oncologist

#### MAIN EDITORIAL ACTIVITY (past)

- Founding Editor and Editor in Chief of Annals of Oncology (1990-2000)

#### TEACHING ACTIVITY

1978 - 2002	Postgraduate teaching, Institut für Medizinische Onkologie, Inselspital, Bern
1976 - 1977	Introduction courses in Internal Medicine for students, Inselspital, Bern
1985 - present	Regular teaching at the European School of Oncology
1988 - present	Chairman, courses on malignant lymphoma, European School of Oncology
January 1993 - 2010	Regular teaching as Professore incaricato at the Scuola di specializzazione oncologica (Training School of Specializing in Oncology), University of Varese
2002 - present	Chairman, Masterclasses, European School of Oncology (ESO)

#### AWARDS

1979	Johann-Georg-Zimmermann-Preis der Medizinischen Hochschule Hannover, Germany
1983	Krebspreis der Stiftung San Salvatore, Lugano, Switzerland
1984	Farmitalia-Preis der Deutschen Krebsgesellschaft
1985	Preis der Schweizerischen Gesellschaft für Innere Medizin for the article „AML, maintenance chemotherapy after early consolidation treatment does not prolong survival“
1991	Distinguished Award European Society for Medical Oncology (ESMO), Florence, Italy
1991	First Award of the Danish Society for Medical Oncology, Copenhagen, Denmark
1992	Greidinger Memorial Lecture, Medical Faculty, Haifa, Israel
1994	Pezcoller Award for special dedication to oncology, Trento, Italy
1998	NDDO Honorary Award, 10 <sup>th</sup> NCI/EORTC Symposium on new drugs, Amsterdam, The Netherlands
1998	Pier Camillo Beccaria Award, Modena, Italy
2001	Waldmann Prize, Medical Faculty, University of Nebraska, Omaha, Nebraska, USA
2004	Paul Carbone Award (INCTR) International Network for Cancer Treatment and Research, Brussels, Belgium
2005	Prize Montaigne, Foundation Toepfer, Hamburg, Germany
2006	Swiss Award (Man of the year) for societal merits, Zurich, Switzerland
2008	Prize Swiss Cancer League, Switzerland
2013	Henry Kaplan Award, 12-ICML, Lugano Switzerland
2013	ESMO Lifetime Achievement Award, Amsterdam, Netherlands
2013	Pavlovsky Lecture, Buenos Aires, Argentina
2016	International Collaboration Outstanding Contribution Award, Chinese Anti-Cancer Association (CACA), Wuhan, China
2021	CAHON Lifetime Award, New York, US

#### HONORARY RECOGNITIONS

2000	First Honorary Member of the European Society for Medical Oncology
2001	Dr. h.c. National University of Nicaragua, Managua, Nicaragua

2004	Dr. h.c. Instituto Superior de Ciencias Medicas de la Habana, Cuba
2006	Honorary Professor Medical University Tianjin, Tianjin, China
2011	Honorary Member Japanese Cancer Association, Tokyo, Japan
2012	Honorary Member Swiss Academy of Medical Sciences, Basel, Switzerland

Among the 620 publications and 4 Textbooks by Prof. F. Cavalli, here the most important ones of the **last years**:

1. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Iliarucci F, Rossi G, Soffiotti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, **Cavalli F**; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. *Lancet* 374(9700):1512-20; 2009
2. Textbook of Medical Oncology 4<sup>th</sup> edition. **Cavalli F**, Kaye SB, Hansen HH, Armitage JO, Piccart-Gebhart MJ. (eds.): Informa Healthcare; 2009
3. Conconi A, Motta M, Bertoni F, Piona C, Stathis A, Wannesson L, Gracia E, Filho VB, Abreu DR, Mian M, Froesch P, Mazzucchelli L, Ghielmini M, **Cavalli F**, Zucca E. Patterns of survival of follicular lymphomas at a single institution through three decades. *Leuk Lymphoma* 51(6):1028-34; 2010
4. Ferreri AJ, Illerhaus G, Zucca E, **Cavalli F**; International Extranodal Lymphoma Study Group. Flows and flaws in primary central nervous system lymphoma. *Nat Rev Clin Oncol* 7(3):125-6; 2010
5. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, **Cavalli F**, Sarris AH, Zucca E. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. *J Clin Oncol* 29(20):2766-72; 2011. Epub 2011 Jun 6
6. **Cavalli F**. An appeal to world cancer leaders: stop cancer now. *Lancet*. Feb 9; 381:425-6; 2013; doi.org/10.106/S0140-6736(13)60059-8; Epub 2013 Feb 4
7. Bonetti P, Testoni M, Scandurra M, Ponzoni M, Piva R, Mensah AA, Rinaldi A, Kwee I, Tibiletti MG, Iqbal J, Greiner TC, Chan WC, Gaidano G, Piris MA, **Cavalli F**, Zucca E, Inghirami G, Bertoni F. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. *Blood*. 2013 Sep 26;122(13):2233-41. doi: 10.1182/blood-2013-01-475772. Epub 2013 Aug 7. Erratum in: *Blood*. 2014 May 8;123(19):3056
8. Cheson BD, Fisher RI, Barrington SF, **Cavalli F**, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphoma Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol*. 2014 Sep 20;32(27):3059-68
9. Zucca E, Bertoni F, Vannata B, **Cavalli F**. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. *Clin Cancer Res*. 2014 Oct 15;20(20):5207-16. doi: 10.1158/1078-0432.CCR-14-0496
10. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoiloova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, **Cavalli F**; LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. *N Engl J Med*. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096
11. **Cavalli F**. Tackling cancer: time for a global response. *Lancet*. 2016 Feb 6;387(10018):e13-4

12. Albin A, DeCensi A, **Cavalli F**, Costa A. Cancer Prevention and Interception: A New Era for Chemopreventive Approaches. *Clin Cancer Res*. 2016 Sep 1;22(17):4322-7. doi: 10.1158/1078-0432.CCR-16-0695. Epub 2016 May 24
13. Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, **Cavalli F**, Johnson PW, Zucca E. A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial. *Blood*. 2017 Jul 18. pii: blood-2017-03-771915. doi: 10.1182/blood-2017-03-771915. [Epub ahead of print]
14. Armitage JO, Gascoyne RD, Lunning MA, **Cavalli F**. Non-Hodgkin lymphoma. *Lancet*. 2017 Jul 15;390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2. Epub 2017 Jan 31. Review
15. Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, **Cavalli F**, Johnson P, Thieblemont C. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. *J Clin Oncol*. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29
16. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørlov J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, **Cavalli F**, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol*. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17
17. Atun R, **Cavalli F**. The global fight against cancer: challenges and opportunities. *Lancet*. 2018 Feb 3;391(10119):412-413. doi: 10.1016/S0140-6736(18)30156-9
18. Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, **Cavalli F**. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. *Ann Oncol*. 2018 Mar 1;29(3):707-714. doi: 10.1093/annonc/mdx764. PMID: 29253068 Clinical Trial
19. Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, **Cavalli F**; LYM-3002 investigators Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. *Lancet Oncol*. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19
20. Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoehstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscazzin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillissen S, Ghielmini M, **Cavalli F**, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. *Blood*. 2020 May 21;135(21):1859-1869. doi: 10.1182/blood.2019003453. PMID: 32267500

## **Professor Franco Cavalli** **M.D., F.R.C.P. (London)**

Franco Cavalli, born in 1942, was the Scientific Director of the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona (Switzerland) until 2017. He created this institute, which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, hematology and an important research division. He is currently still President of the Foundation, which manages the Institute of Oncology Research (IOR), located in Bellinzona (Switzerland). He is Professor (*Titularprofessor*) of medical oncology at the Medical Faculty in Bern (Switzerland) and honorary Professor at different universities. He has an international reputation for the treatment of and research into malignant lymphoma and new drugs. Every second year he organizes in Lugano the International Conference on Malignant Lymphoma, which is the most important congress on this topic worldwide. He has been very active also in the field of the clinical evaluation of new cancer drugs. The quality of his work has been recognized by the award of 24 national and international prizes, including the Petzcoller Award for special dedication to oncology and the ESMO Lifetime Achievement Award. He has published more than 600 articles in peer-reviewed journals and has contributed to many books on cancer, including the Textbook of Medical Oncology, which he edited together with S. Kaye (London), H.H. Hansen (Copenhagen) and D. Armitage (Omaha, Nebraska). He was Founding Editor and Editor-in-Chief of *Annals of Oncology*, Europe's premier medical oncology journal, from 1990 to 2000, and he is on the Editorial Board of several other journals. In 1996, he founded the International Extranodal Lymphoma Study Group (IELSG), which encompasses now more than 300 institutions in 4 continents. IELSG is the leading cooperative group in the field of the biological and clinical studies in the field of extranodal lymphomas.

Franco Cavalli was President of the Swiss Group for Clinical Research (SAKK), of the Swiss Cancer League and is Chairman of the Scientific Committee of the European School of Oncology (ESO) and of the World Oncology Forum (WOF). He was President of the International Union Against Cancer (UICC) between 2006 and 2008. He was member of WHO committee of selection of essential medicines for cancers from 2015 to 2021.

He was member of the Swiss Parliament between 1995 and 2007 and Head of the socialist parliamentary group from 1999 to 2002.

Since 1985 he has been leading medical and humanitarian projects in Central America and Cuba with the association AMCA (Associazione per l'aiuto medico al Centro America) and MediCuba, both funded by him. He has been, since 2012, President of MediCuba Europe. For UICC he led medical projects in Vietnam, Tanzania and Kirgizstan.